NCT02401945View on ClinicalTrials.gov

A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

June 22, 2016

Study Completion Date

October 31, 2016

Conditions
Age-Related Macular Degeneration
Interventions
DRUG

DE-120

DRUG

Aflibercept

Trial Locations (14)

Unknown

Phoenix

Bakersfield

Walnut Creek

Golden

Altamonte Springs

Fort Myers

Indianapolis

Portsmouth

Charlotte

Dallas

Houston

McAllen

San Antonio

Salt Lake City

All Listed Sponsors
lead

Santen Inc.

INDUSTRY

NCT02401945 - A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter